Kamfanin magunguna na Japan Otsuka (Otsuka) kwanan nan ya sami labari mai daɗi a cikin sassan ƙa'idodin Amurka, FDA ta amince da maganin cutar kansa sabon magani Lo 3 watanni a gaba.nsurf (trifluridine / tipiracil, FTD / TPI) ana amfani dashi don kula da marasa lafiya da ciwon daji na metastatic metastatic (mCRC) waɗanda ba sa amsa wasu hanyoyin kwantar da hankali (chemotherapy da biotherapy).
Lonsurf (lambar ci gaba TAS-102) sabon maganin antimetabolite ne, wanda ya ƙunshi anti-tumor nucleoside analog FTD (trifluridine) da thymidine phosphorylase inhibitor TPI (tipiracil). Daga cikin su, FTD na iya maye gurbin thymine kai tsaye a cikin DNA sau biyu a lokacin maimaita DNA, wanda ke haifar da rashin aiki na DNA kuma yana tsoma baki tare da haɗin DNA cell cell; TPI na iya hana thymus phosphorylase da ke da alaƙa da bazuwar FTD kuma ya rage lalata FTD, Kula da ƙwayar jini na FTD.
Amincewar Lonsurf ya dogara ne akan ingantattun bayanai daga na ƙasa-da-ƙasa, bazuwar, makafi biyu-biyu na nazari na III. Binciken ya ƙunshi marasa lafiya 800 waɗanda aka yi musu magani a baya maganin ciwon daji (mCRC). A cikin binciken, an ba da izini ga marasa lafiya don karɓar Lonsurf + mafi kyawun maganin tallafi (BSC) ko placebo + BSC har sai yanayin ya tabarbare ko kuma tasirin sakamako ya zama wanda ba za a iya jurewa ba. Bayanan sun nuna cewa gaba ɗaya rayuwa na ƙungiyar jiyya ta Lonsurf ya fi tsayi fiye da na ƙungiyar placebo (OS: 7.1 watanni vs 5.3 watanni), yayin da rayuwa ba tare da ci gaba ba kuma ya fi tsayi (PFS: 2 months vs 1.7 months) , Ya kai matakin farko da na biyu na binciken. Dangane da aminci, mafi yawan illolin da ƙungiyar maganin Lonsurf ke yi sun haɗa da anemia, rauni, matsananciyar gajiya, tashin zuciya, rage cin abinci, gudawa, amai, ciwon ciki, da zazzabi.
A baya can, Lonsurf ya sami amincewa daga hukumomin sarrafawa na Japan a cikin Maris 2014; a Turai, Otsuka ya gabatar da takardar neman Lonsurf ga Tarayyar Turai a cikin watan Maris na wannan shekarar, kuma kamfanin ya sanya hannu kan wata yarjejeniya tare da abokin aikinsa Servier Don yarjejeniyar dala miliyan 130, Servier zai kasance da alhakin sayar da Lonsurf na kasuwanci a cikin Nahiyar Turai. .
Kasuwar magance cututtukan daji ta duniya (CRC) za ta kai dala biliyan 9.4 a shekarar 2020.
Dangane da rahoton binciken da kamfanin bincike na kasuwar duniya GBI Research ya fitar, kasuwar maganin cutar kansa ta duniya (CRC) za ta kula da karamin ci gaba cikin 'yan shekaru masu zuwa (2014-2020), ta kai dala biliyan 9.4 ta shekarar 2020 A cikin lokacin hasashen, yawan ci gaban shekara-shekara (CAGR) ya kasance 1.8%, kuma darajar kasuwar kasuwar a shekarar 2013 ta kai dala biliyan 8.3.
Rahoton ya yi nuni da cewa, wannan ci gaban zai fi faruwa ne a manyan kasashe takwas da suka ci gaba, da suka hada da Amurka, da Japan, da Canada, da kuma kasashen Turai biyar (Birtaniya, Faransa, Jamus, Spain, da Italiya). A cikin 2013, Amurka tana da kaso mafi girma na kasuwar maganin cutar kansa ta duniya (CRC), wanda ke da kashi 44.1%, sai Japan (14.7%) da Jamus (11.9%), Spain (4.1%) tare da mafi ƙarancin kasuwa. raba. Ana sa ran waɗannan ƙasashe za su yi girma a hankali, ban da Japan, wanda zai yi girma cikin sauri (CAGR na 5%).
Rahoton ya nuna cewa a lokacin tsinkayen, maganin Roche blockbuster Avastin (sunan da ya dace: bevacizumab, bevacizumab) da Merck (Merck KGaA) kwayar kwayar Erbitux (sunan da aka sani: cetuximab), Cetuximab) takaddama a manyan kasuwanni sun ƙare, za su inganta tallan yarda da kasuwa na masu rahusa mai rahusa, wanda zai iyakance ci gaban kasuwannin duniya na maganin cutar kansa. Roche chemotherapeutic drug Xeloda (Xeloda, generic name: capecitabine, capecitabine) magungunan ƙwayoyi waɗanda aka lissafa a cikin manyan kasuwanni ana tsammanin zai iyakance haɓakar kasuwar maganin kansar kai tsaye ta duniya.
Duk da haka, manazarcin GBI Saurabh Sharma ya yi nuni da cewa ko da takardar shaidar Avastin ta kare, maganin zai ci gaba da kasancewa kan gaba a kasuwar kula da cutar sankara ta duniya (CRC) har zuwa shekarar 2020. Saurabh ya bayyana cewa a halin yanzu ana amfani da Avastin sosai a layin farko da na biyu. -layin magani na ciwon daji na colorectal, ba tare da la'akari da matsayin K-Ras na majiyyaci ba. Kodayake an sayar da masu hana haɓakar haɓakar haɓakar haɓakar epidermal (EGFR) don maganin nau'in daji na K-Ras. ciwan kansa ; Avastin zai ci gaba da mamaye kasuwanninta wajen kula da yanayin ƙirar K-Ras mai haɗari da yanayin ciwan mutant.
Rahoton ya yi nuni da cewa, ana sa ran sabon maganin cutar sankara na baki na Bayer Stivarga (regorafenib) zai kasance daya daga cikin manyan abubuwan da ke haifar da ci gaba a kasuwar maganin cutar sankara ta duniya (CRC). Wannan ya fi girma saboda tsammanin faɗaɗa jiyya na asibiti na miyagun ƙwayoyi a matsayin magani na kulawa Ana amfani da miyagun ƙwayoyi don maganin layin farko na ciwon daji na launin fata (mCRC) wanda aka cire metastases na hanta. Stivarga shine mai hanawa na baka da yawa a halin yanzu da aka jera a manyan kasuwanni kamar Amurka, EU, da Japan. Bugu da kari, an amince da maganin cutar daji na Dapeng Pharmaceutical na Japan Lonsurf (TAS-102) don yin magani na layi na uku da na huɗu a Japan a cikin 2014, kuma Amgen's monoclonal antibody Vectibix (panitumumab) kuma Amurka ta amince da shi. . Kuma EU ta amince da jiyya ta farko. Karɓar kasuwar waɗannan sabbin magunguna za su haɓaka haɓakar kasuwar jiyya ta duniya.
Rahoton ya kuma nuna cewa a lokacin hasashen (2014-2020), ana sa ran sabbin magungunan bututun mai da yawa za su sauka a kasuwa, ciki har da Lilly's monoclonal antibody Cyramza (ramucirumab), Boehringer Ingelheim na maganin angiokinase sau uku nintedanib, XBiotech Kamfanin na monoclonal antibody Xilonix . Koyaya, waɗannan magungunan za su shiga cikin layin tsere na biyu da na uku da na huɗu kuma ba za su sami babban tasiri a kan kasuwar gaba ɗaya ba. Magungunan da aka kera a halin yanzu a kasuwa zasu ci gaba da jin daɗin mamaye kasuwar kamar yadda aka haɗa su a baya kuma mafi fa'ida jiyya ta farko.
